XENE - Company ID 0001582313
The table below shows Xenon Pharmaceuticals Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$88.90M | -$61.65M | -$46.19M | -$34.41M | -$18.43M | -$20.71M |
| Capital expenditure | $133.00K | $43.00K | $188.00K | $2.21M | $212.00K | $404.00K |
| Investing cash flow | -$407.28M | $34.51M | -$43.19M | $46.62M | -$48.89M | -$55.10M |
| Dividends paid | - | - | - |
Xenon Pharmaceuticals Inc. reported operating cash flow of -$279.12M for fiscal year 2025. That is down 53.9% from -$181.39M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$28.73M (FY 2017) to -$279.12M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $843.01M | $1.15M | $0.00 | - | $7.88M | $118.72M |